ArticleScientific reports2016
Generation of 2,000 breast cancer metabolic landscapes reveals a poor prognosis group with active serotonin production.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Article
- Uncovering genetic variations in HTR2A and miRNAs drivers of breast cancer risk in African American women.Journal of breast cancer research · 2026Article
- The Clinicopathological and Prognostic Significance of the Expression of PD-L1 and MET Genes in Breast Cancer: Potential Therapeutic Targets.Current cancer drug targets · 2025Article
- Tryptophanyl-tRNA synthetase-1 (WARS-1) depletion and high tryptophan concentration lead to genomic instability in Caenorhabditis elegans.Cell death discovery · 2024Article
- Neuroendocrine pathways and breast cancer progression: a pooled analysis of somatic mutations and gene expression from two large breast cancer cohorts.BMC cancer · 2022Article
- Article
- Role of Extracellular Vimentin in Cancer-Cell Functionality and Its Influence on Cell Monolayer Permeability Changes Induced by SARS-CoV-2 Receptor Binding Domain.International journal of molecular sciences · 2021Article
- Intra-tumoural lipid composition and lymphovascular invasion in breast cancer via non-invasive magnetic resonance spectroscopy.European radiology · 2021Article
- The Role of Serotonin in Breast Cancer Stem Cells.Molecules (Basel, Switzerland) · 2021Review
- Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis.International journal of molecular sciences · 2021Review
- Effect of SSRI exposure on the proliferation rate and glucose uptake in breast and ovary cancer cell lines.Scientific reports · 2021Article
- Low Entropy Sub-Networks Prevent the Integration of Metabolomic and Transcriptomic Data.Entropy (Basel, Switzerland) · 2020Article
- Cell metabolomics to study the function mechanism of Cyperus rotundus L. on triple-negative breast cancer cells.BMC complementary medicine and therapies · 2020Article
- Molecular Adaptations in the Rat Dorsal Striatum and Hippocampus Following Abstinence-Induced Incubation of Drug Seeking After Escalated Oxycodone Self-Administration.Molecular neurobiology · 2019Article
- Platelets, Thrombo-Inflammation, and Cancer: Collaborating With the Enemy.Frontiers in immunology · 2019Review
- Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases.Scientific reports · 2018Article
- 5-HT serotonin receptors modulate mitogenic signaling and impact tumor cell viability.Molecular and clinical oncology · 2018Article
- Framework and resource for more than 11,000 gene-transcript-protein-reaction associations in human metabolism.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth.ACS medicinal chemistry letters · 2017Article
- Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major roadblock in the effective treatment of cancers is their heterogeneity, whereby multiple molecular landscapes are classified as a single disease. To explore the contribution of cellular metabolism to cancer heterogeneity, we analyse the Metabric dataset, a landmark genomic and transcriptomic study of 2,000 individual breast tumours, in the context of the human genome-scale metabolic network. We create personalized metabolic landscapes for each tumour by exploring sets of active reactions that satisfy constraints derived from human biochemistry and maximize congruency with the Metabric transcriptome data. Classification of the personalized landscapes derived from 997 tumour samples within the Metabric discovery dataset reveals a novel poor prognosis cluster, reproducible in the 995-sample validation dataset. We experimentally follow mechanistic hypotheses resulting from the computational study and establish that active serotonin production is a major metabolic feature of the poor prognosis group. These data support the reconsideration of concomitant serotonin-specific uptake inhibitors treatment during breast cancer chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.